{"id":"NCT02788279","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)","officialTitle":"A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-05","primaryCompletion":"2018-03-09","completion":"2018-12-26","firstPosted":"2016-06-02","resultsPosted":"2019-06-18","lastUpdate":"2019-12-11"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody","otherNames":[]},{"type":"DRUG","name":"Cobimetinib","otherNames":[]},{"type":"DRUG","name":"Regorafenib","otherNames":[]}],"arms":[{"label":"Atezolizumab","type":"EXPERIMENTAL"},{"label":"Cobimetinib + Atezolizumab","type":"EXPERIMENTAL"},{"label":"Regorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization up to death due to any cause (up to approximately 20 months)","effectByArm":[{"arm":"Regorafenib","deltaMin":8.51,"sd":null},{"arm":"Cobimetinib + Atezolizumab","deltaMin":8.87,"sd":null},{"arm":"Atezolizumab","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9871"},{"comp":"OG000 vs OG002","p":"0.3360"},{"comp":"OG000 vs OG001","p":"0.9686"},{"comp":"OG000 vs OG002","p":"0.3553"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":25},"locations":{"siteCount":73,"countries":["United States","Australia","Belgium","Canada","Hong Kong","Italy","Poland","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["37741832","36310331","31003911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":90},"commonTop":["DIARRHOEA","FATIGUE","RASH","DECREASED APPETITE","NAUSEA"]}}